216 related articles for article (PubMed ID: 33432358)
1. Real-world experience of effectiveness of non-medical switch from originator to biosimilar rituximab in rheumatoid arthritis.
Melville AR; Md Yusof MY; Fitton J; Garcia-Montoya L; Bailey L; Dass S; Emery P; Buch MH; Saleem B
Rheumatology (Oxford); 2021 Aug; 60(8):3679-3688. PubMed ID: 33432358
[TBL] [Abstract][Full Text] [Related]
2. Real-world experience of rituximab biosimilar GP2013 in rheumatoid arthritis patients naïve to or switched from reference rituximab.
Łosińska K; Korkosz M; Pripp AH; Haugeberg G
Rheumatol Int; 2023 May; 43(5):881-888. PubMed ID: 36922417
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial.
Shim SC; Božić-Majstorović L; Berrocal Kasay A; El-Khouri EC; Irazoque-Palazuelos F; Cons Molina FF; Medina-Rodriguez FG; Miranda P; Shesternya P; Chavez-Corrales J; Wiland P; Jeka S; Garmish O; Hrycaj P; Fomina N; Park W; Suh CH; Lee SJ; Lee SY; Bae YJ; Yoo DH
Rheumatology (Oxford); 2019 Dec; 58(12):2193-2202. PubMed ID: 31184752
[TBL] [Abstract][Full Text] [Related]
4. Tocilizumab and rituximab have similar effectiveness and are both superior to a second tumour necrosis factor inhibitor in rheumatoid arthritis patients who discontinued a first TNF inhibitor.
Santos-Faria D; Tavares-Costa J; Eusébio M; Leite Silva J; Ramos Rodrigues J; Sousa-Neves J; Duarte AC; Lopes C; Valido A; Dinis J; Freitas J; Santiago M; Ferreira R; Ganhão S; Miranda L; Peixoto D; Teixeira F; Alcino S; Afonso C; Santos MJ
Acta Reumatol Port; 2019; 44(2):103-113. PubMed ID: 31243259
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial.
Nabi H; Georgiadis S; Loft AG; Hendricks O; Jensen DV; Andersen M; Chrysidis S; Colic A; Danebod K; Hussein MR; Kalisz MH; Kristensen S; Lomborg N; Manilo N; Munk HL; Pedersen JK; Raun JL; Mehnert F; Krogh NS; Hetland ML; Glintborg B
Ann Rheum Dis; 2021 Nov; 80(11):1400-1409. PubMed ID: 33926921
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis.
Park W; Suh CH; Shim SC; Molina FFC; Jeka S; Medina-Rodriguez FG; Hrycaj P; Wiland P; Lee EY; Shesternya P; Kovalenko V; Myasoutova L; Stanislav M; Radominski S; Lim MJ; Choe JY; Lee SJ; Lee SY; Kim SH; Yoo DH
BioDrugs; 2017 Aug; 31(4):369-377. PubMed ID: 28600696
[TBL] [Abstract][Full Text] [Related]
7. Safety and effectiveness of biosimilar of Rituximab CT-P10 in the treatment of cryoglobulinemic vasculitis: the MARBLe study (Mixed cryoglobulinemiA Rituximab BiosimiLar).
Vacchi C; Visentini M; Gragnani L; Fraticelli P; Tavoni A; Filippini D; Saccardo F; Lauletta G; Colantuono S; Atzeni F; Pioltelli P; Manfredi A; Casato M; Zignego AL; Monti G; Pietrogrande M; Galli M; Sebastiani M
Intern Emerg Med; 2021 Jan; 16(1):149-156. PubMed ID: 32524338
[TBL] [Abstract][Full Text] [Related]
8. Brief Report: Safety and Immunogenicity of Rituximab Biosimilar GP 2013 After Switch From Reference Rituximab in Patients With Active Rheumatoid Arthritis.
Tony HP; Krüger K; Cohen SB; Schulze-Koops H; Kivitz AJ; Jeka S; Vereckei E; Cen L; Kring L; Kollins D
Arthritis Care Res (Hoboken); 2019 Jan; 71(1):88-94. PubMed ID: 30295429
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial.
Smolen JS; Cohen SB; Tony HP; Scheinberg M; Kivitz A; Balanescu A; Gomez-Reino J; Cen L; Poetzl J; Shisha T; Kollins D
Rheumatology (Oxford); 2021 Jan; 60(1):256-262. PubMed ID: 32699904
[TBL] [Abstract][Full Text] [Related]
10. A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis.
Smolen JS; Cohen SB; Tony HP; Scheinberg M; Kivitz A; Balanescu A; Gomez-Reino J; Cen L; Zhu P; Shisha T
Ann Rheum Dis; 2017 Sep; 76(9):1598-1602. PubMed ID: 28637670
[TBL] [Abstract][Full Text] [Related]
11. Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial.
Park W; Božić-Majstorović L; Milakovic D; Berrocal Kasay A; El-Khouri EC; Irazoque-Palazuelos F; Molina FFC; Shesternya P; Miranda P; Medina-Rodriguez FG; Wiland P; Jeka S; Chavez-Corrales J; Garmish O; Linde T; Rekalov D; Hrycaj P; Krause A; Fomina N; Piura O; Abello-Banfi M; Suh CH; Shim SC; Lee SJ; Lee SY; Kim SH; Yoo DH
MAbs; 2018; 10(6):934-943. PubMed ID: 30010481
[TBL] [Abstract][Full Text] [Related]
12. Characteristics and outcomes of rheumatoid arthritis patients who started biosimilar infliximab.
Sung YK; Cho SK; Kim D; Won S; Choi CB; Bang SY; Hong SJ; Kim HA; Koh EM; Lee HS; Suh CH; Yoo DH; Bae SC
Rheumatol Int; 2017 Jun; 37(6):1007-1014. PubMed ID: 28214924
[TBL] [Abstract][Full Text] [Related]
13. [The role of laboratory biomarkers in monitoring of rituximab biosimilar therapy (Acellbia, "BIOCAD") in patients with rheumatoid arthritis].
Avdeeva AS; Cherkasova MV; Kusevich DA; Rybakova VV; Artyuhov AS; Dashinimaev EB; Chichasova NV; Nasonov EL
Ter Arkh; 2019 May; 91(5):26-33. PubMed ID: 32598673
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial.
Yoo DH; Suh CH; Shim SC; Jeka S; Molina FFC; Hrycaj P; Wiland P; Lee EY; Medina-Rodriguez FG; Shesternya P; Radominski S; Stanislav M; Kovalenko V; Sheen DH; Myasoutova L; Lim MJ; Choe JY; Lee SJ; Lee SY; Kim SH; Park W
BioDrugs; 2017 Aug; 31(4):357-367. PubMed ID: 28612179
[TBL] [Abstract][Full Text] [Related]
15. The retrospective evaluation of efficacy and safety data after switching from originator rituximab to biosimilar rituximab (CT-P10) in patients diagnosed with systemic lupus erythematosus: a single-center experience.
Ekin A; Mısırcı S; Coşkun BN; Yağız B; Dalkılıç E; Pehlivan Y
Eur Rev Med Pharmacol Sci; 2024 May; 28(10):3513-3522. PubMed ID: 38856126
[TBL] [Abstract][Full Text] [Related]
16. Costs associated with non-medical switching from originator to biosimilar etanercept in patients with rheumatoid arthritis in the UK.
Tarallo M; Onishchenko K; Alexopoulos ST
J Med Econ; 2019 Nov; 22(11):1162-1170. PubMed ID: 31373527
[No Abstract] [Full Text] [Related]
17. To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry.
Glintborg B; Loft AG; Omerovic E; Hendricks O; Linauskas A; Espesen J; Danebod K; Jensen DV; Nordin H; Dalgaard EB; Chrysidis S; Kristensen S; Raun JL; Lindegaard H; Manilo N; Jakobsen SH; Hansen IMJ; Dalsgaard Pedersen D; Sørensen IJ; Andersen LS; Grydehøj J; Mehnert F; Krogh NS; Hetland ML
Ann Rheum Dis; 2019 Feb; 78(2):192-200. PubMed ID: 30396903
[TBL] [Abstract][Full Text] [Related]
18. Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure: results from The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
Silva-Fernández L; De Cock D; Lunt M; Low AS; Watson KD; ; Symmons DPM; Hyrich KL
Rheumatology (Oxford); 2018 Sep; 57(9):1533-1540. PubMed ID: 28968862
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of rituximab biosimilar (CT-P10) in IgG4-related disease: an observational prospective open-label cohort study.
Della-Torre E; Lanzillotta M; Campochiaro C; Di-Colo G; Mancuso G; Capurso G; Falconi M; Dagna L
Eur J Intern Med; 2021 Feb; 84():63-67. PubMed ID: 33386207
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of non-medical switch from adalimumab bio-originator to SB5 biosimilar and from ABP501 adalimumab biosimilar to SB5 biosimilar in patients with chronic inflammatory arthropathies: a monocentric observational study.
Scrivo R; Castellani C; Mancuso S; Sciarra G; Giardina F; Bevignani G; Ceccarelli F; Spinelli FR; Alessandri C; Di Franco M; Riccieri V; Priori R; Conti F
Clin Exp Rheumatol; 2023 Mar; 41(3):613-619. PubMed ID: 35916302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
